Iris Nederlof - Netherlands Canc Inst, Div Tumor Biol & Immunol, Amsterdam, Netherlands

基本信息

浏览量：7

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 32 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Temporal and Spatial Composition of the Tumor Microenvironment Predicts Response to Immune Checkpoint Inhibition

Noah F Greenwald,Iris Nederlof, Cameron Sowers,Daisy Yi Ding, Seongyeol Park,Alex Kong,Kathleen E Houlahan,Sricharan Reddy Varra, Manon de Graaf,Veerle Geurts,Candace C Liu, Jolene S Ranek,Leonie Voorwerk,Michiel de Maaker,Adam Kagel,Erin McCaffrey,Aziz Khan,Christine Yiwen Yeh,Christine Camacho Fullaway,Zumana Khair,Yunhao Bai,Hadeesha Piyadasa,Tyler Risom,Alea Delmastro,Felix J Hartmann,Lise Mangiante, Cristina Sotomayor-Vivas,Ton N Schumacher,Zhicheng Ma,Marc Bosse, Marc J van de Vijver,Robert Tibshirani,Hugo M Horlings,Christina Curtis,Marleen Kok,Michael Angelo

bioRxiv the preprint server for biology (2025)

引用0浏览0WOS引用

Triple-negative Breast Cancer Modifies the Systemic Immune Landscape and Alters Neutrophil Functionality

Noor A. M. Bakker,Hannah Garner,Ewald van Dyk,Elisa Champanhet, Chris Klaver, Maxime Duijst,Leonie Voorwerk,Iris Nederlof, Rosie Voorthuis,Marte C. Liefaard,Marja Nieuwland,Iris de Rink,Onno B. Bleijerveld,Hendrika M. Oosterkamp,Lodewyk F. A. Wessels,Marleen Kok,Karin E. de Visser

npj Breast Cancerno. 1 (2025): 1-17

引用0浏览0WOSNATURE引用

the Temporal Influence of the Tumor Microenvironment in Response to Checkpoint Blockade

Noah F. Greenwald,Iris Nederlof,Hugo Horlings,Marleen Kok,Christina Curtis,Michael Angelo

Cancer Researchno. 6_Supplement (2024): 3894-3894

引用0浏览0引用

LBA11 Neoadjuvant Nivolumab/relatlimab or Nivolumab/ipilimumab in Triple Negative Breast Cancer with High Tumor-Infiltrating Lymphocytes (Tils)

I. Nederlof, A.L. Rolfes, R.C.A.M. Gielen,G. Awada, M.V. Dongen,H.M. Horlings,K. Van De Vijver,C.A. Drukker,F. van Duijnhoven,M. Lopez-Yurda,I. Mandjes,R.M. Mann,C.E. Loo,C.U. Blank,T.N. Schumacher,R.F. Salgado,M. Kok

Annals of Oncology（2024）

引用0浏览0引用

Automated Classification of Cellular Expression in Multiplexed Imaging Data with Nimbus

J Lorenz Rumberger,Noah F Greenwald, Jolene S Ranek, Potchara Boonrat, Cameron Walker,Jannik Franzen,Sricharan Reddy Varra,Alex Kong, Cameron Sowers,Candace C Liu,Inna Averbukh,Hadeesha Piyadasa,Rami Vanguri,Iris Nederlof, Xuefei Julie Wang,David Van Valen,Marleen Kok, Travis J Hollmann,Dagmar Kainmueller,Michael Angelo

bioRxiv the preprint server for biology (2024)

引用0浏览0WOS引用

Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Early-Stage Triple-Negative Breast Cancer: a Phase 2 Adaptive Trial

Iris Nederlof,Olga I. Isaeva, Manon de Graaf, Robbert C. A. M. Gielen,Noor A. M. Bakker, Adrianne L. Rolfes,Hannah Garner,Bram Boeckx,Joleen J. H. Traets,Ingrid A. M. Mandjes,Michiel de Maaker,Thomas van Brussel,Maksim Chelushkin,Elisa Champanhet,Marta Lopez-Yurda,Koen van de Vijver,Jose G. van den Berg,Ingrid Hofland, Natasja Klioueva,Ritse M. Mann,Claudette E. Loo,Frederieke H. van Duijnhoven, Victoria Skinner, Sylvia Luykx,Emile Kerver,Ekaterina Kalashnikova,Marloes G. J. van Dongen,Gabe S. Sonke,Sabine C. Linn,Christian U. Blank,Karin E. de Visser,Roberto Salgado,Lodewyk F. A. Wessels,Caroline A. Drukker,Ton N. Schumacher,Hugo M. Horlings,Diether Lambrechts,Marleen Kok

NATURE MEDICINE (2024)

引用0浏览0WOSNATURE引用

163MO Single-cell T Cell Dynamics Induced by Neoadjuvant Nivolumab +/- Ipilimumab in Early Triple Negative Breast Cancer with Tumor-Infiltrating Lymphocytes (BELLINI Trial)

O.I. Isaeva,I. Nederlof,M. de Graaf,B. Boeckx, J. Traets,I.A.M. Mandjes,K. Van De Vijver, M. Chelushkin,C. Drukker, M.V. Dongen,G.S. Sonke,S.C. Linn,C.U. Blank,K.E. de Visser,R.F. Salgado,L.F.A. Wessels,T.N. Schumacher,H.M. Horlings,D. Lambrechts,M. Kok

Immuno-Oncology and Technology (2023): 100622

引用0浏览0引用

Facts and Hopes in Immunotherapy for Early-Stage Triple-Negative Breast Cancer

Iris Nederlof,Leonie Voorwerk,Marleen Kok

Clinical Cancer Research（2023）

引用7浏览0WOS引用

LBA13 Nivolumab and ipilimumab in early-stage triple negative breast cancer (TNBC) with tumor-infiltrating lymphocytes (TILs): First results from the BELLINI trial

I. Nederlof,O.I. Isaeva, N. Bakker,M. de Graaf,R.F. Salgado, N. Klioueva,K. Van De Vijver,F. van Duijnhoven,E. Kalashnikova,S. Willingham, S. Luykx,C.E. Loo, E. Kerver,G.S. Sonke,C.U. Blank,R. Mann,S.C. Linn,D. Lambrechts,H. Horlings,M. Kok

Annals of Oncology (2022)

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn